DSpace About DSpace Software 日本語
 

GINMU >
01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2021年度 >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10564/4011

Title: CRISPR-Cas9-Mediated TIM3 Knockout in Human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells.
Other Titles: CRISPR-Cas9を用いてTIM3をノックアウトしたヒトNK細胞の膠芽腫細胞株に対する抗腫瘍効果の検討
Authors: Morimoto, Takayuki
Nakazawa, Tsutomu
Matsuda, Ryosuke
Nishimura, Fumihiko
Nakamura, Mitsutoshi
Yamada, Shuichi
Nakagawa, Ichiro
Park, Young-Soo
Tsujimura, Takahiro
Nakase, Hiroyuki
Keywords: TIM3
CRISPR-Cas9
NK cell
glioblastoma
Issue Date: 28-Mar-2021
Publisher: MDPI
Citation: International journal of molecular sciences Vol.22 No.7 Article No.3489 (2021 Mar)
Abstract: Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults. Natural Killer (NK) cells are potent cytotoxic effector cells against tumor cells inducing GBM cells; therefore, NK cell based- immunotherapy might be a promising target in GBM. T cell immunoglobulin mucin family member 3 (TIM3), a receptor expressed on NK cells, has been suggested as a marker of dysfunctional NK cells. We established TIM3 knockout in NK cells, using the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9). Electroporating of TIM3 exon 2- or exon 5-targeting guide RNA- Cas9 protein complexes (RNPs) inhibited TIM3 expression on NK cells with varying efficacy. T7 endonuclease I mutation detection assays showed that both RNPs disrupted the intended genome sites. The expression of other checkpoint receptors, i.e., programmed cell death 1 (PD1), Lymphocyte-activation gene 3 (LAG3), T cell immunoreceptor with Ig and ITIM domains (TIGIT), and TACTILE (CD96) were unchanged on the TIM3 knockout NK cells. Real time cell growth assays revealed that TIM3 knockout enhanced NK cell-mediated growth inhibition of GBM cells. These results demonstrated that TIM3 knockout enhanced human NK cell mediated cytotoxicity on GBM cells. Future, CRISPR-Cas9 mediated TIM3 knockout in NK cells may prove to be a promising immunotherapeutic alternative in patient with GBM.
Description: 博士(医学)・甲第828号・令和4年3月15日
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
URI: http://hdl.handle.net/10564/4011
ISSN: 14220067
Academic Degrees and number: 24601A828
Degree-granting date: 2022-03-15
Degree name: 博士(医学)
Degree-granting institutions: 奈良県立医科大学
Appears in Collections:2021年度

Files in This Item:

File Description SizeFormat
01甲828本文の要旨.pdf甲828本文の要旨1.41 MBAdobe PDFView/Open
02甲828審査要旨.pdf甲828審査要旨638.83 kBAdobe PDFView/Open
03甲828本文.pdf甲828本文3.65 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback